Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.82 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.59 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.59 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 7/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.58 |
| ▸ | ERBB3 | P21860 | 7/20 | 0.58 |
| ▸ | ERBB4 | Q15303 | 7/20 | 0.58 |
| ▸ | TEK | Q02763 | 6/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | RET | P07949 | 4/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1940568 | 0.93 | PDGFRB (0.77) | PDGFRBNTRK1NTRK2NTRK3EGFR | |
| SCHEMBL1941166 | 0.92 | PDGFRB (0.84) | PDGFRBNTRK1NTRK2NTRK3EGFR | |
| SCHEMBL1939510 | 0.92 | PDGFRB (0.84) | PDGFRBNTRK1NTRK2NTRK3EGFR | |
| SCHEMBL1939988 | 0.91 | PDGFRB (0.77) | PDGFRBNTRK1NTRK2NTRK3EGFR | |
| SCHEMBL1940776 | 0.91 | PDGFRB (0.79) | PDGFRBNTRK1NTRK2NTRK3EGFR | |
| SCHEMBL1941187 | 0.90 | PDGFRB (0.75) | PDGFRBNTRK1NTRK2NTRK3EGFR | |
| SCHEMBL1941784 | 0.90 | PDGFRB (1.00) | PDGFRBNTRK1NTRK2NTRK3EGFR | |
| SCHEMBL1941117 | 0.90 | PDGFRB (0.78) | PDGFRBNTRK1NTRK2NTRK3EGFR | |
| SCHEMBL1940895 | 0.90 | PDGFRB (0.86) | PDGFRBNTRK1NTRK2NTRK3EGFR | |
| SCHEMBL1939749 | 0.90 | PDGFRB (0.83) | PDGFRBNTRK1NTRK2NTRK3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578751-B1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PROD INC (US) | 2011-06-15 | — | — | EP | claimed |
| US-7271262-B2 | Pyrrolopyrimidine derivatives | PFIZER INC (US) | 2007-09-18 | — | — | US | claimed |
| EP-1578751-A1 | PYRROLOPYRIMIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | PFIZER INC | 2005-02-17 | — | — | US | claimed |
| WO-2004056830-A1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| EP-1578751-B1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PROD INC (US) | 2011-06-15 | — | — | EP | disclosed |
| US-7271262-B2 | Pyrrolopyrimidine derivatives | PFIZER INC (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1578751-A1 | PYRROLOPYRIMIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| WO-2004056830-A1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | CCNA1, CCNT1, TP53 | PDGFRB 2465/4885NTRK1 4135/4885NTRK2 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.